Investigational drug · Phase 2
[18F]F-AraG
Also called: PET tracer, 2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine, VisAcT
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer Disease (AD), Covid19, SARS-CoV Infection.
Phase 2Last checked: Nov 20, 2026Latest source record: May 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
n/a
Any phase or sponsor naming "[18F]F-AraG"
First trial start
2021
Apr 15, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "[18F]F-AraG", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease (AD)
- Covid19
- SARS-CoV Infection
Approved drugs for the same conditions: Alzheimer's disease · Neurology · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "[18F]F-AraG" as an intervention, largest first.
- Imaging Immune Activation in COVID-19
NCT04815096 · Phase 2 · Recruiting · CellSight Technologies, Inc. · 80 participants · primary completion Oct 1, 2027
- [18F]F-AraG PET Imaging in Alzheimer's Disease
NCT07611357 · Phase 2 · Not yet recruiting · CellSight Technologies, Inc. · 10 participants · primary completion Sep 16, 2029
Newest research
PubMed records naming it or its code names, newest first.
- Discovery of benzoxazole derivatives as novel α-synuclein aggregate ligands with potential for PET tracer development.
Wang Y, Qin J, Zhang Y, et al. · Eur J Med Chem 2027
- A Head-to-Head Comparison of Detection Rate and Tumor Uptake of FAPI, PSMA, and FDG PET/CT in Newly Diagnosed High-risk Prostate Cancer.
Zhang W, Dong Y, Xu L, et al. · Clin Nucl Med 2026
- Neuroimaging of indoleamine 2,3-dioxygenase 1 (Ido1) in Alzheimer's disease: Development of a novel 18F-labeled PET tracer.
Cheng H, Narayan NS, Wang Y, et al. · Mater Today Bio 2026
- A DPP6-Targeted PET Tracer for Non-Invasive Imaging of Transplanted Human Islets.
Khalil A, Roca-Rivada A, Vasylovska S, et al. · Diabetes Obes Metab 2026
- Osteoarthritis and fibroblast activation: an imaging study assessing feasibility and reliability of whole-body 68 Ga-FAPI PET-CT for structural osteoarthritis evaluation.
Roemer AK, Heiss R, Schmidkonz C, et al. · Skeletal Radiol 2026
- First-in-human evaluation of [18F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [68Ga]Ga-PSMA-617.
He J, Wang Y, Tang W, et al. · Ann Med 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.